Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia

Exclusion Criteria

• •inability to provide informed consent
• •substance and alcohol abuse
• •significant medical illness, including congestive heart failure, severe hepatic impairment, severe Chronic Obstructive Pulmonary Disease (COPD), severe sleep apnea, severe cardiovascular disease or renal disease
• •current history of diabetes mellitus or thyroid disease
• •women who are pregnant, breastfeeding, or who are unwilling or unable to use an effective form of birth control during the entire study
• •psychiatrically unstable, patients with major depression
• •patients treated with medications known to affect glucose tolerance such as birth control pills containing norgestrel, steroids, beta blockers, anti-inflammatory drugs (including daily aspirin and ibuprofen), thiazide diuretics; and agents that induce weight loss will be excluded from the study
• •treatment with fluvoxamine in the or ketoconazole past two weeks
• •treatment with fluconazole (a strong CYP2C9 inhibitor).
• •subjects treated with ziprasidone and aripiprazole conventional agents
• •treatment with sedative-hypnotics such as barbiturates, zolpidem, eszopiclone, zaleplon. The use of stable daily doses of benzodiazepines is allowed.
• •known hypersensitivity to ramelteon or any of its components